Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Treace Medical Concepts, Inc. (TMCI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed medical technology company focused on bunion and related midfoot deformities, Treace uses these filings to report financial results, material agreements, governance changes and risk factors relevant to TMCI stockholders.
Investors can review annual reports on Form 10‑K for a detailed discussion of Treace’s business, including its Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, minimally invasive Nanoplasty and Percuplasty systems, SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants, IntelliGuide patient specific technology, and associated risk factors and market considerations. Quarterly reports on Form 10‑Q provide interim financial statements, management’s discussion and analysis and updates on operations and liquidity.
Current reports on Form 8‑K capture specific material events, such as the entry into new senior secured term loan and revolving credit agreements, repayment and termination of prior credit facilities, earnings releases for quarterly periods and changes in the composition or roles of the board of directors. These filings outline key terms of financing arrangements, including collateral, interest rates, covenants and potential implications for dividend payments.
Users can also monitor proxy statements and related materials for information on governance, board structure and executive compensation, as well as Section 16 filings such as Form 4 for reports of insider transactions in TMCI shares. Stock Titan’s platform pairs these documents with AI‑powered summaries that explain complex sections, highlight notable items and help readers quickly understand how new filings may relate to Treace’s bunion‑focused business, financial condition and capital structure.
With real‑time updates from EDGAR and structured access to key forms, this page serves as a central resource for analyzing TMCI’s regulatory history and ongoing disclosure record.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 6,260,000 shares of Treace Medical Concepts, Inc., representing 9.91% of the outstanding common stock based on 63,173,126 shares outstanding as of July 31, 2025. The reported position is held directly by Armistice Capital Master Fund Ltd. with Armistice Capital acting as investment manager and Steven Boyd as managing member. The Reporting Persons disclaim sole voting or dispositive power; all voting and dispositive power is reported as shared (6,260,000 shares). The Master Fund is identified as the direct holder and retains rights to dividends or sale proceeds.
Scot Michael Elder, Chief Legal & Compliance Officer and corporate secretary of Treace Medical Concepts (TMCI), reported a Form 4 disclosing an equity transaction dated 08/09/2025. The filing lists a transaction coded "F" involving 10,515 shares at a reported price of $0. After the reported transaction, Mr. Elder beneficially owns 566,149 shares, held directly.
The filing states the beneficial ownership total includes 480,103 restricted stock units and indicates no derivative securities were reported. This disclosure describes the insider's reported change in non-derivative equity holdings and the composition of the reported stake.
Mark Hair, Chief Financial Officer of Treace Medical Concepts (TMCI), reported a change in beneficial ownership of common stock on 08/09/2025. The Form 4 records a disposition of 22,212 shares with a transaction code labeled "F" and a reported transaction price of $0. After the reported transaction the filing shows Mr. Hair beneficially owns 518,964 shares directly; that total expressly includes 421,228 restricted stock units. The filing discloses the magnitude of the ownership change but does not provide explanation for the transaction code or the zero price.
Sean F. Scanlan, identified as Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a common stock transaction dated 08/09/2025 on a Form 4. The filing records a transaction coded F and shows the reporting line items 9,814 with a marker D and a post-transaction beneficial ownership total of 373,807 shares held directly.
The form includes an explanatory footnote that the beneficial ownership figure includes 284,798 restricted stock units. The filing was executed by an attorney-in-fact on behalf of Mr. Scanlan as indicated on the form.
Aaron Berutti, SVP, Sales at Treace Medical Concepts (TMCI), reported a change in beneficial ownership that results in 205,092 shares held beneficially. The filing shows a transaction dated 08/09/2025 listing 4,907 common shares with a recorded price of $0.
The reported total ownership explicitly includes 181,955 restricted stock units, per the form explanation. The disclosure is a Form 4 insider report reflecting an officer-level change in equity holdings; the filing does not provide additional context about the nature of the $0 price or whether the change arose from vesting, issuance, conversion, or another mechanism.